Cargando…

Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain

BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putat...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Qi, Niu, Yimin, Matsumoto, Kinzo, Tsuneyama, Koichi, Tanaka, Ken, Miyata, Takeshi, Yokozawa, Takako
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564934/
https://www.ncbi.nlm.nih.gov/pubmed/23082896
http://dx.doi.org/10.1186/1472-6882-12-188
_version_ 1782258387691503616
author Zhao, Qi
Niu, Yimin
Matsumoto, Kinzo
Tsuneyama, Koichi
Tanaka, Ken
Miyata, Takeshi
Yokozawa, Takako
author_facet Zhao, Qi
Niu, Yimin
Matsumoto, Kinzo
Tsuneyama, Koichi
Tanaka, Ken
Miyata, Takeshi
Yokozawa, Takako
author_sort Zhao, Qi
collection PubMed
description BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putative mechanism(s) underlying the effects. METHODS: Seven-week-old db/db mice received daily administration of CTS (375 – 750 mg/kg, p.o.) and the reference drug tacrine (THA: 2.5 mg/kg, i.p.) during an experimental period of 7 weeks. From the age of 9-week-old, the animals underwent the novel object recognition test, the modified Y-maze test, and the water maze test to elucidate cognitive performance and the elevated plus maze test to elucidate anxiety-related behavior. After completing behavioral studies, Western blotting and immunohistochemical studies were conducted. RESULTS: Compared with age-matched non-diabetic control strain (m/m) mice, db/db mice exhibited impaired cognitive performance and an increased level of anxiety. CTS ameliorated cognitive and emotional deficits of db/db mice, whereas THA improved only cognitive performance. The phosphorylated levels of Akt and PKCα in the hippocampus were significantly lower and higher, respectively, in db/db mice than in m/m mice. Expression levels of the hippocampal cholinergic marker proteins and the number of the septal cholinergic neurons were also reduced in db/db mice compared with those in m/m mice. Moreover, the db/db mice had significantly reduced levels of vasculogenesis/angiogenesis factors, vascular endothelial growth factor (VEGF), VEGF receptor type 2, platelet-derived growth factor-B, and PDGF receptor β, in the hippocampus. CTS and THA treatment reversed these neurochemical and histological alterations caused by diabetes. CONCLUSION: These results suggest that CTS ameliorates diabetes-induced cognitive deficits by protecting central cholinergic and VEGF/PDGF systems via Akt signaling pathway and that CTS exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or VEGF/PDGF systems in db/db mice.
format Online
Article
Text
id pubmed-3564934
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35649342013-02-08 Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain Zhao, Qi Niu, Yimin Matsumoto, Kinzo Tsuneyama, Koichi Tanaka, Ken Miyata, Takeshi Yokozawa, Takako BMC Complement Altern Med Research Article BACKGROUND: Diabetes is one of the risk factors for cognitive deficits such as Alzheimer’s disease. To obtain a better understanding of the anti-dementia effect of chotosan (CTS), a Kampo formula, we investigated its effects on cognitive and emotional deficits of type 2 diabetic db/db mice and putative mechanism(s) underlying the effects. METHODS: Seven-week-old db/db mice received daily administration of CTS (375 – 750 mg/kg, p.o.) and the reference drug tacrine (THA: 2.5 mg/kg, i.p.) during an experimental period of 7 weeks. From the age of 9-week-old, the animals underwent the novel object recognition test, the modified Y-maze test, and the water maze test to elucidate cognitive performance and the elevated plus maze test to elucidate anxiety-related behavior. After completing behavioral studies, Western blotting and immunohistochemical studies were conducted. RESULTS: Compared with age-matched non-diabetic control strain (m/m) mice, db/db mice exhibited impaired cognitive performance and an increased level of anxiety. CTS ameliorated cognitive and emotional deficits of db/db mice, whereas THA improved only cognitive performance. The phosphorylated levels of Akt and PKCα in the hippocampus were significantly lower and higher, respectively, in db/db mice than in m/m mice. Expression levels of the hippocampal cholinergic marker proteins and the number of the septal cholinergic neurons were also reduced in db/db mice compared with those in m/m mice. Moreover, the db/db mice had significantly reduced levels of vasculogenesis/angiogenesis factors, vascular endothelial growth factor (VEGF), VEGF receptor type 2, platelet-derived growth factor-B, and PDGF receptor β, in the hippocampus. CTS and THA treatment reversed these neurochemical and histological alterations caused by diabetes. CONCLUSION: These results suggest that CTS ameliorates diabetes-induced cognitive deficits by protecting central cholinergic and VEGF/PDGF systems via Akt signaling pathway and that CTS exhibits the anxiolytic effect via neuronal mechanism(s) independent of cholinergic or VEGF/PDGF systems in db/db mice. BioMed Central 2012-10-20 /pmc/articles/PMC3564934/ /pubmed/23082896 http://dx.doi.org/10.1186/1472-6882-12-188 Text en Copyright ©2012 Zhao et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zhao, Qi
Niu, Yimin
Matsumoto, Kinzo
Tsuneyama, Koichi
Tanaka, Ken
Miyata, Takeshi
Yokozawa, Takako
Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title_full Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title_fullStr Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title_full_unstemmed Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title_short Chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and VEGF/PDGF mechanisms in the brain
title_sort chotosan ameliorates cognitive and emotional deficits in an animal model of type 2 diabetes: possible involvement of cholinergic and vegf/pdgf mechanisms in the brain
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564934/
https://www.ncbi.nlm.nih.gov/pubmed/23082896
http://dx.doi.org/10.1186/1472-6882-12-188
work_keys_str_mv AT zhaoqi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT niuyimin chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT matsumotokinzo chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT tsuneyamakoichi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT tanakaken chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT miyatatakeshi chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain
AT yokozawatakako chotosanamelioratescognitiveandemotionaldeficitsinananimalmodeloftype2diabetespossibleinvolvementofcholinergicandvegfpdgfmechanismsinthebrain